- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06366672
Evaluating the Human Immune Response to the JYNNEOS Vaccine
April 10, 2024 updated by: Philip Mudd, Washington University School of Medicine
Evaluating the Durability of the Human Immune Response to the JYNNEOS Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine
This study is designed to evaluate the magnitude and duration of the human adaptive immune response to the JYNNEOS Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine in the blood, lung mucosa, skin and bone marrow.
Study Overview
Status
Not yet recruiting
Conditions
Detailed Description
Orthopoxvirus vaccination leads to very high magnitude antigen-specific T cell responses and neutralizing antibody responses that can be detected in blood decades after vaccination.
Despite a large number of previous studies of human immune responses to Modified Vaccinia Ankara (MVA) vaccination in blood, very few of these previous studies evaluate the human mucosal immune response to MVA in the lung and skin, or the immune response to MVA vaccination in the bone marrow.
The development of methods to explore human immune responses in these key immunologic compartments now allows the evaluation of the induction of immune responses in these human tissues using the MVA vaccine system.
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Philip Mudd, MD, PhD
- Phone Number: 314-273-1576
- Email: pmudd@wustl.edu
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University in Saint Louis School of Medicine Emergency Care and Research Core
-
Contact:
- Jamie Mills
- Phone Number: 314-305-1054
- Email: jamiem@wustl.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 18-60 year old otherwise healthy participants
Exclusion Criteria:
- Prisoners
- Participants unable to provide full written informed consent
- Previous receipt of a smallpox or monkeypox vaccine
- Previous infection with monkeypox
- Receipt of any vaccine in the 28 days prior to the first study procedure or planned receipt of any vaccine outside of those provided in the current study before completion of the study day 42 visit.
- Immunocompromise (primary or secondary due to other medical conditions or medications)
- Previous organ transplant
- Active malignancy
- Pregnancy
- < 4 weeks post-partum or actively breastfeeding
- Female participants who are not actively on hormonal contraception or do not have an intrauterine device in place
- Body Mass Index > 40
- Current smokers
- History of a known chronic pulmonary, cardiovascular, renal, hepatic, hematologic or metabolic disorder. Participants with isolated treated hypertension as the only cardiovascular disorder may be included in the study.
- History of a chronic neurologic or neurodevelopmental condition. This does not exclude potential participants with chronic back pain or previous disk herniation/back surgery, only participants with documented weakness, quadriplegia or paraplegia. This exclusion criterion also does not exclude from the study participants with recurrent migraine headaches as the only chronic neurologic condition.
- Pulse oxygen saturation value of 92% or less on room air at study enrollment or on the day of bronchoscopy
- Any significant infiltrate or pleural effusion on upright posterior-anterior and lateral chest x-ray imaging performed on the day of bronchoscopy
- International Normalized Ratio value greater than 1.4 or a Partial Thromboplastin Time value of greater than 40 seconds at study enrollment
- Platelet count of less than 100,000 at study enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MVA-BN vaccinated
MVA-BN vaccine administered: day 0 and day 28 Phlebotomy: within 30 days prior to first vaccine dose, day 0, day 14, day 28, day 35, day 42, day 56, day 90, day 110, day 150, day 210, day 395 Research bronchoscopy: within 30 days prior to first vaccine dose, day 42, day 210, day 395 Skin punch biopsy: within 30 days prior to first vaccine dose, day 42, day 210, day 395 Bone marrow aspiration: within 30 days prior to first vaccine dose, day 56, day 110, day 210, day 395
|
live, nonreplicating vaccine delivered according to the FDA approved package insert
Research blood draw
Outpatient research bronchoscopy with bronchoalveolar lavage and endobronchial biopsy performed with conscious sedation.
Skin punch biopsy performed with topical anesthesia.
Bone marrow aspiration performed with local anesthesia.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in magnitude of the MVA-BN antigen-specific T cell response in the blood
Time Frame: Change from day 42 to day 395
|
Change from day 42 to day 395
|
Change in magnitude of the MVA-BN antigen-specific antibody response in blood plasma
Time Frame: Change from day 42 to day 395
|
Change from day 42 to day 395
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in magnitude of the MVA-BN antigen-specific T cell response in the lower airways
Time Frame: Change from day 42 to day 395
|
Change from day 42 to day 395
|
Change in magnitude of the MVA-BN antigen-specific antibody response in bronchoalveolar lavage fluid
Time Frame: Change from day 42 to day 395
|
Change from day 42 to day 395
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the magnitude and surface phenotype of T cells in the blood, airspace, and skin over time
Time Frame: Through study completion on day 395
|
Through study completion on day 395
|
Evaluate the magnitude and surface phenotype of B cells in the blood and bone marrow over time.
Time Frame: Through study completion on day 395
|
Through study completion on day 395
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Philip Mudd, MD, PhD, Washington University School of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2024
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
April 4, 2024
First Submitted That Met QC Criteria
April 10, 2024
First Posted (Actual)
April 16, 2024
Study Record Updates
Last Update Posted (Actual)
April 16, 2024
Last Update Submitted That Met QC Criteria
April 10, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202312043
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Virus Diseases
-
Institute of Tropical Medicine, BelgiumCompletedTransmission | Zika Virus | Zika Virus Disease | Virus SheddingBelgium
-
TakedaCompletedFlavivirus Infections | Healthy Participants | Virus, Zika | Zika Virus DiseaseUnited States, Puerto Rico
-
U.S. Army Medical Research and Development CommandActive, not recruiting
-
Emergent BioSolutionsCompletedZika Virus Infection | Zika Virus DiseaseCanada
-
National Institute of Allergy and Infectious Diseases...CompletedHealthy | Epstein Barr Virus InfectionUnited States
-
U.S. Army Medical Research and Development CommandCompleted
-
Valneva Austria GmbHEmergent BioSolutionsCompletedZika Virus Infection | Zika VirusUnited States
-
Merck Sharp & Dohme LLCCompletedVaricella Virus Infection
-
RTI InternationalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsUnknown
-
Sun Yat-sen UniversityWuzhou Red Cross Hospital; Zhongshan People's Hospital, Guangdong, ChinaRecruiting
Clinical Trials on JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection
-
National Institute of Allergy and Infectious Diseases...Active, not recruiting
-
SIGA TechnologiesUnited States Department of DefenseCompleted
-
National Institute of Allergy and Infectious Diseases...Active, not recruitingMonkeypoxUnited States, Puerto Rico
-
Womack Army Medical CenterUnited States Naval Medical Center, San Diego; C.R.Darnall Army Medical CenterNot yet recruitingMyopericarditis | Small Pox
-
National Institute of Allergy and Infectious Diseases...Institut National de Recherche Biomédicale. Kinshasa, République Démocratique...RecruitingMonkeypoxCongo, The Democratic Republic of the
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingMonkey Pox | Monkey DiseasesFrance
-
Centers for Disease Control and PreventionBavarian Nordic; Kinshasa School of Public Health; Ministry of Public Health,...Active, not recruitingMonkeypox Virus InfectionCongo, The Democratic Republic of the
-
PfizerRecruitingShingles | Human | Herpes Zoster InfectionUnited States
-
Fundación Instituto de Estudios de Ciencias de...Instituto de Investigación Biomédica de Salamanca; Spanish Clinical Research...CompletedHepatitis B | Hepatitis | Hepatitis, Viral, Human | Hepatitis B ImmunizationSpain
-
Fluart Innovative Vaccine Ltd, HungaryCompleted